Learning Objectives:

  1. To describe the methods and outcomes of the EMPA-KIDNEY trial
  2. Describe the strengths and limitations of the EMPA-KIDNEY trial
  3. To evaluate benefit of SGLT2 on progression of kidney disease or death from cardiovascular causes


Session date: 
12/16/2022 - 12:00pm to 1:00pm CST
Via Zoom
5841 S. Maryland Ave
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Nader Ismail, DO